CONMED - CNMD Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CNMD shares.
View CNMD analyst ratings or view top-rated stocks.

1 analysts have issued 1-year price targets for CONMED's stock. Their CNMD share price forecasts range from $106.00 to $106.00. On average, they anticipate the company's stock price to reach $106.00 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price.
View analysts price targets for CNMD or view top-rated stocks among Wall Street analysts.

CONMED's stock was trading at $88.64 at the beginning of the year. Since then, CNMD stock has increased by 8.0% and is now trading at $95.76.
View the best growth stocks for 2023 here.

CONMED saw a increase in short interest in December. As of December 15th, there was short interest totaling 3,550,000 shares, an increase of 7.3% from the November 30th total of 3,310,000 shares. Based on an average trading volume of 412,700 shares, the days-to-cover ratio is currently 8.6 days.
View CONMED's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our CNMD earnings forecast.

CONMED will be holding an earnings conference call on Thursday, February 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

CONMED announced a quarterly dividend on Monday, December 5th. Investors of record on Friday, December 16th will be paid a dividend of $0.20 per share on Thursday, January 5th. This represents a $0.80 annualized dividend and a yield of 0.84%. The ex-dividend date of this dividend is Thursday, December 15th.
Read our dividend analysis for CNMD.

CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.83%.
Read our dividend analysis for CNMD.

CONMED issued an update on its FY 2023 earnings guidance on Thursday, December, 15th. The company provided earnings per share (EPS) guidance of $3.20-$3.50 for the period, compared to the consensus earnings per share estimate of $3.39. The company issued revenue guidance of $1.17 billion-$1.23 billion, compared to the consensus revenue estimate of $1.21 billion.

CONMED trades on the New York Stock Exchange (NYSE) under the ticker symbol "CNMD."

CONMED's stock is owned by a number of retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (0.98%), Congress Asset Management Co. MA (0.55%), Mountain Pacific Investment Advisers Inc. ID (0.41%), Peregrine Capital Management LLC (0.38%), Moody Aldrich Partners LLC (0.17%) and AMI Asset Management Corp (0.16%).
View institutional ownership trends.

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CNMD stock can currently be purchased for approximately $95.76.

CONMED (NYSE:CNMD) has a market capitalization of $2.92 billion and generates $1.01 billion in revenue each year. The company earns $62.54 million in net income (profit) each year or ($2.95) on an earnings per share basis.

The company employs 3,800 workers across the globe.

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The official website for the company is www.conmed.com. The company can be reached via phone at (727) 392-6464 or via fax at 315-797-0321.